COMMUNIQUÉS West-GlobeNewswire

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
12/02/2025
DOVER, Del., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced [...]
Voting Rights and Shares Capital of the Company
12/02/2025
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Feb. 12, 2025 (GLOBE NEWSWIRE [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
12/02/2025
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 12 févr. 2025 (GLOBE NEWSWIRE) -- Paris, France, le 12 février 2025 Place de cotation [...]
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors
12/02/2025
HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology [...]
Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for March 3, 2025 at 4:30 P.M. Eastern Time
12/02/2025
GERMANTOWN, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose [...]
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs
12/02/2025
– Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S ( [...]
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
12/02/2025
SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial [...]
Amwell® Announces Results for Fourth Quarter and Full Year 2024
12/02/2025
BOSTON, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the fourth quarter and full [...]
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
12/02/2025
Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and Orphan Drug Designation Open-label arm (infant participants < 1 year old) [...]
Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update
12/02/2025
Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein Focusing on [...]
Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia
12/02/2025
Study Progresses to Fourth Higher 90 mg/m 2 Dose Cohort Compelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast Count After One Treatment Cycle HOUSTON, Feb. 12, 2025 (GLOBE NEWSWIRE [...]
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
12/02/2025
– Strong early U.S. YORVIPATH ® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million – Following pre-NDA meeting with FDA, on track to submit TransCon ™ CNP NDA for [...]
atai Life Sciences Announces Proposed Public Offering of Common Shares
12/02/2025
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders [...]
Mdxhealth to Present Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on February 26
12/02/2025
Company to Host Conference Call with Live Q&A, February 26, 2025, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 12, 2025 ( GlobeNewswire ) – MDxHealth SA (NASDAQ: MDXH), a leading precision [...]
CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim
12/02/2025
New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
12/02/2025
ORION CORPORATION STOCK EXCHANGE RELEASE – MAJOR SHAREHOLDER ANNOUNCEMENTS 12 FEBRUARY 2025 at 21.00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
12/02/2025
Media Release COPENHAGEN, Denmark; February 12, 2025 Genmab filed Form 20-F for the financial year 2024 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial [...]
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
12/02/2025
NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, [...]
SAFE GROUP - CHIFFRE D’AFFAIRES 2024
12/02/2025
CHIFFRE D’AFFAIRES 2024 Fleurieux-sur-l’Arbresle - France - le 12 février 2025 à 18h30. Safe Group publie son chiffre d’affaires annuel consolidé réalisé sur l’exercice 2024. En K€ 2024 (1) 2023 (2) Variation en % [...]

Pages